FDA Regulation
Nutriband Advances Abuse-Deterrent Fentanyl Patch Toward FDA Submission Following Regulatory Feedback
Nutriband Inc. has received critical FDA guidance confirming the regulatory pathway for its AVERSA™ Fentanyl abuse-deterrent transdermal system, marking a significant step forward in addressing the opioid crisis through innovative pharmaceutical technology.
Nutriband Secures $5.3 Million Through Warrant Exercises, Bolstering AVERSA™ Fentanyl Development
Nutriband Inc. raised $5.3 million through voluntary warrant exercises at $6.43 per share, demonstrating strong investor confidence in its abuse-deterrent transdermal patch technology AVERSA™ Fentanyl ahead of its FDA submission.
Nutriband Advances Fentanyl Patch Development with FDA Meeting as CEO Pursues Presidential Nomination
Nutriband Inc. progresses its abuse-deterrent fentanyl patch AVERSA™ through FDA regulatory pathways while maintaining leadership continuity during CEO Gareth Sheridan's temporary departure for Irish presidential candidacy.
United Health Products Awaits FDA Response on Regulatory Hurdles
United Health Products, Inc. faces regulatory challenges with the FDA over its Investigational Device Exemption application and a 2015 Warning Letter, impacting its path to market for its hemostatic gauze product.
FDA's Rapid AI Integration Highlights Urgency in Modernizing Regulatory Processes
The U.S. Food and Drug Administration's deployment of the Elsa AI tool marks a significant step towards modernizing regulatory reviews, with Lantern Pharma CEO Panna Sharma noting the aggressive timeline reflects the agency's urgency.
FDA's Accelerated Launch of AI Tool Elsa Sparks Transparency and Oversight Concerns
The FDA's early release of its AI tool, Elsa, aims to enhance efficiency in drug development processes but has ignited debates over the lack of transparency and potential oversight issues.